Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
- Registration Number
- NCT00403169
- Lead Sponsor
- The Cleveland Clinic
- Brief Summary
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
- Detailed Description
OBJECTIVES:
* Evaluate the best response in patients with advanced or unresectable renal cell carcinoma (RCC) treated with lenalidomide.
* Evaluate the response duration, time to tumor progression, and survival of patients with advanced RCC treated with lenalidomide.
* Evaluate the safety of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive oral lenalidomide daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Lenalidomide for Advanced RCC lenalidomide 25 mg/day Lenalidomide for 21 days per cycle.
- Primary Outcome Measures
Name Time Method Overall response
- Secondary Outcome Measures
Name Time Method Toxicity
Trial Locations
- Locations (1)
Case Comprehensive Cancer Center
🇺🇸Cleveland, Ohio, United States